95331-19-4

Basic information

• Product Name: 1-Decanol, 10-(phenylmethoxy)-
• CAS NO: 95331-19-4
• Molecular Formula: C17H28O2
• Molecular Weight: 264.408
• Mol File: 95331-19-4.mol
• Article Data: 32

Chemical Properties

• CAS DataBase Reference: 1-Decanol, 10-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Decanol, 10-(phenylmethoxy)-(95331-19-4)
• EPA Substance Registry System: 1-Decanol, 10-(phenylmethoxy)-(95331-19-4)

Safety Data

• Hazardous Substances Data: 95331-19-4(Hazardous Substances Data)

Upstream product

• 112-47-0 1,10-Decanediol 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 

Downstream Products

• 112-47-0 1,10-Decanediol 
• 2485-71-4 13-methyltetradecanoic acid 
• 887604-03-7 1-((dodec⁽¹²⁾ynyloxy)methyl)benzene 
• 17833-52-2 (S)-9-hydroxyhexadecanoic acid 

Relevant articles and documents

Interaction of 10-(octyloxy) decyl-2-(trimethylammonium) ethyl phosphate with mimetic membranes and cytotoxic effect on leukemic cells

10-(Octyloxy) decyl-2-(trimethylammonium) ethyl phosphate (ODPC) is an alkylphospholipid that can interact with cell membranes because of its amphiphilic character. We describe here the interaction of ODPC with liposomes and its toxicity to leukemic cells

Nitrile Synthesis by Aerobic Oxidation of Primary Amines and in situ Generated Imines from Aldehydes and Ammonium Salt with Grubbs Catalyst

Herein, a Grubbs-catalyzed route for the synthesis of nitriles via the aerobic oxidation of primary amines is reported. This reaction accommodates a variety of substrates, including simple primary amines, sterically hindered β,β-disubstituted amines, allylamine, benzylamines, and α-amino esters. Reaction compatibility with various functionalities is also noted, particularly with alkenes, alkynes, halogens, esters, silyl ethers, and free hydroxyl groups. The nitriles were also synthesized via the oxidation of imines generated from aldehydes and NH4OAc in situ. (Figure presented.).

LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.